FDA approves J&J’s Darzalex for smoldering multiple myeloma

Lei Lei Wu / endpoints - The FDA on Thursday approved Johnson & Johnson’s Darzalex injection for high-risk smoldering multiple myeloma, a condition in which people have abnormal cells that could turn into myeloma but don’t have ...

AI Summary: The FDA has approved a subcutaneous formulation of daratumumab—marketed as Darzalex—for patients with high‐risk smoldering multiple myeloma, promising a more convenient administration route. This decision is set to improve patient quality of life and streamline treatment protocols in an area of oncology where every minute counts.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Statins Rarely Cause Listed Side Effects, Review Confirms / 3 months

AHA25: Breakthroughs in Cardiovascular and Cardio‐Oncology / 6 months

Intellia CRISPR Trial Fatality Raises Safety Concerns / 6 months

Apixaban linked to lower bleeding than rivaroxaban in head‑to‑head study / 2 months

Hormone therapy adds no clear benefit to salvage radiotherapy / 2 months

Life-extending prostate cancer drug to be offered to thousands in England / 4 months

DEA extends telehealth controlled substance flexibilities for 2026 / 4 months